Tăng biểu hiện và tuyển mộ HDAC1 vào nhân tế bào trong ung thư tuyến tiền liệt kháng hormoon

10.1002/cncr.10593

10.1002/cncr.11380

10.1002/(SICI)1097-0142(19990815)86:4<657::AID-CNCR15>3.0.CO;2-9

10.1002/ijc.2910480206

10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H

10.1006/excr.2000.5080

10.1126/science.272.5260.408

10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7

10.1016/S0968-0004(00)01551-6

Bartl S, 1997, Identification of mouse histone deacetylase 1 as a growth factor‐inducible gene, Mol Cell Biol, 17, 5033, 10.1128/MCB.17.9.5033

10.1093/emboj/21.11.2672

10.1093/emboj/20.7.1739

10.1016/0303-7207(94)90118-X

10.1038/sj.onc.1205663

Krenacs L, 1996, Immunohistochemical diagnosis of T‐cell lymphomas in paraffin sections, J Cell Pathol, 1, 125

10.1002/path.1711730413

Bouras T, 2001, Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu, Cancer Res, 61, 903

10.2144/01315bi01

10.1002/cyto.990140503

10.1002/cyto.1097

Wainstein MA, 1994, CWR22: Androgen‐dependent xenograft model derived from a primary human prostatic carcinoma, Cancer Res, 54, 6049

Nagabhushan M, 1996, CWR22: The first human prostate cancer xenograft with strongly androgen‐dependent and relapsed strains both in vivo and in soft agar, Cancer Res, 56, 3042

10.1006/gyno.2000.5744

10.1002/cncr.11366

10.1002/path.993

10.1128/MCB.18.12.7185

10.1016/S1043-2760(01)00438-6

10.1093/jnci/92.15.1210

Weidle UH, 2000, Inhibition of histone deacetylases: A new strategy to target epigenetic modifications for anticancer treatment, Anticancer Res, 20, 1471

Butler LM, 2000, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Res, 60, 5165

Carducci MA, 2001, A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120‐h infusion schedule, Clin Cancer Res, 7, 3047

Patnaik A, 2002, A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies, Clin Cancer Res, 8, 2142

Sandor V, 2002, Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms, Clin Cancer Res, 8, 718

Ferrara FF, 2001, Histone deacetylase‐targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia, Cancer Res, 61, 2

10.1016/S0003-4975(00)02421-8

10.1074/jbc.M203423200

10.1006/bbrc.2001.5639

10.1111/j.1349-7006.2001.tb02153.x

10.1074/jbc.M201174200

10.1038/35042612

Doetzlhofer A, 1999, Histone deacetylase 1 can repress transcription by binding to Sp1, Mol Cell Biol, 19, 5504, 10.1128/MCB.19.8.5504

10.1093/emboj/19.4.662

10.1074/jbc.M003106200

Medina V, 1997, Induction of caspase‐3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c‐dependent pathway, Cancer Res, 57, 3697

10.1016/S0021-9258(17)44885-X

10.1002/ijc.10082

10.1007/978-3-642-78771-3_1

10.1038/bjc.1989.16

10.1002/1097-0142(19900201)65:3<538::AID-CNCR2820650326>3.0.CO;2-G

10.1016/0046-8177(92)90107-E

10.1002/pros.2990200406

Isaacs JT, 1997, Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer, Am J Pathol, 150, 1511

10.1002/1097-4644(20001201)79:3<471::AID-JCB120>3.0.CO;2-O

10.1016/S0959-8049(96)00418-2

10.1046/j.1464-410X.2001.00117.x

10.1038/labinvest.3780133

10.1016/S0046-8177(98)90208-8

Nagle RB, 1987, Cytokeratin characterization of human prostatic carcinoma and its derived cell lines, Cancer Res, 47, 281

10.1016/S0022-5347(17)39903-2